Export 246 results:
Author [ Title(Asc)] Type Year
Filters: First Letter Of Last Name is W  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
G
Normand, P., Lapierre, P., Tisa, L. S., Gogarten, J. P., et al. (2007). Genome characteristics of facultatively symbiotic Frankia sp. strains reflect host range and host plant biogeography. Genome Research, 17(1), 7 - 15.
Normand, P., Lapierre, P., Tisa, L. S., Gogarten, J. P., et al. (2007). Genome characteristics of facultatively symbiotic Frankia sp. strains reflect host range and host plant biogeography. Genome Research, 17(1), 7 - 15.
Becker, F., Van El, C. G., Ibarreta, D., Zika, E., et al. (2011). Genetic testing and common disorders in a public health framework: How to assess relevance and possibilities. European Journal of Human Genetics, 19(SUPPL. 1), S6 - S44.
Altland, K., Benson, M. D., Costello, C. E., Ferlini, A., et al. (2007). Genetic microheterogeneity of human transthyretin detected by IEF. Electrophoresis, 28(12), 2053 - 2064.
Neto, J. L., Lee, J. - M., Afridi, A., Gillis, T., et al. (2017). Genetic contributors to intergenerational CAG repeat instability in Huntington’s disease knock-in mice. Genetics, 205(2), 503 - 516.
Gonçalves, A. F., Dias, N. G., Moransard, M., Correia, R., et al. (2010). Gelsolin is required for macrophage recruitment during remyelination of the peripheral nervous system. GLIA, 58(6), 706 - 715.
E
Soares, T. S., Watanabe, R. M. O., Tanaka-Azevedo, A. M., Torquato, R. J. S., et al. (2012). Expression and functional characterization of boophilin, a thrombin inhibitor from Rhipicephalus (Boophilus) microplus midgut. Veterinary Parasitology, 187(3-4), 521 - 528.
Benninger, Y., Thurnherr, T., Pereira, J. A., Krause, S., et al. (2007). Essential and distinct roles for cdc42 and rac1 in the regulation of Schwann cell biology during peripheral nervous system development. Journal of Cell Biology, 177(6), 1051 - 1061.
Earnshaw, W. C., Allshire, R. C., Black, B. E., Bloom, K., et al. (2013). Esperanto for histones: CENP-A, not CenH3, is the centromeric histone H3 variant. Chromosome Research, 21(2), 101 - 106.
Earnshaw, W. C., Allshire, R. C., Black, B. E., Bloom, K., et al. (2013). Esperanto for histones: CENP-A, not CenH3, is the centromeric histone H3 variant. Chromosome Research, 21(2), 101 - 106.
Earnshaw, W. C., Allshire, R. C., Black, B. E., Bloom, K., et al. (2013). Esperanto for histones: CENP-A, not CenH3, is the centromeric histone H3 variant. Chromosome Research, 21(2), 101 - 106.
Earnshaw, W. C., Allshire, R. C., Black, B. E., Bloom, K., et al. (2013). Esperanto for histones: CENP-A, not CenH3, is the centromeric histone H3 variant. Chromosome Research, 21(2), 101 - 106.
Earnshaw, W. C., Allshire, R. C., Black, B. E., Bloom, K., et al. (2013). Esperanto for histones: CENP-A, not CenH3, is the centromeric histone H3 variant. Chromosome Research, 21(2), 101 - 106.
Fontenete, S., Barros, J., Madureira, P., Figueiredo, C., et al. (2015). Erratum to: Mismatch discrimination in fluorescent in situ hybridization using different types of nucleic acids (Applied Microbiology and Biotechnology, 10.1007/s00253-015-6389-4). Applied Microbiology and Biotechnology, 99(9), 4117.
Castelo-Branco, P., Furger, A., Wollerton, M., Smith, C., et al. (2004). Erratum: Polypyrimidine tract binding protein modulates efficiency of polyadenylation (Molecular and Cellular Biology (2004) 24, 10 (4174-4183)). Molecular and Cellular Biology, 24(15), 6889.
Braunlin, E., Rosenfeld, H., Kampmann, C., Johnson, J., et al. (2013). Enzyme replacement therapy for mucopolysaccharidosis VI: Long-term cardiac effects of galsulfase (Naglazyme®) therapy. Journal of Inherited Metabolic Disease, 36(2), 385 - 394.
Braunlin, E., Rosenfeld, H., Kampmann, C., Johnson, J., et al. (2012). Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme ®) therapy. Journal of Inherited Metabolic Disease.
Decker, C., Yu, Z. - F., Giugliani, R., Schwartz, I. V. D., et al. (2010). Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. Journal of Pediatric Rehabilitation Medicine, 3(2), 89 - 100.
Decker, C., Yu, Z. - F., Giugliani, R., Schwartz, I. V. D., et al. (2010). Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. Journal of Pediatric Rehabilitation Medicine, 3(2), 89 - 100.
Harmatz, P., Yu, Z. - F., Giugliani, R., Schwartz, I. V. D., et al. (2010). Enzyme replacement therapy for mucopolysaccharidosis VI: Evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. Journal of Inherited Metabolic Disease, 33(1), 51 - 60.
Harmatz, P., Yu, Z. - F., Giugliani, R., Schwartz, I. V. D., et al. (2010). Enzyme replacement therapy for mucopolysaccharidosis VI: Evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. Journal of Inherited Metabolic Disease, 33(1), 51 - 60.
Harmatz, P., Giugliani, R., Schwartz, I., Guffon, N., et al. (2006). Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-l. Journal of Pediatrics, 148(4), 533 - 533.e.

Pages


Home | Site Map | Contacts | Credits | Privacy & Cookies | Intranet | Social Networks |


rua alfredo allen, 208, 4200-135 porto - portugal | tel +351 220 408 800 | email: info@i3s.up.pt | © copyright 2010 ibmc